Literature DB >> 25540894

Microenvironmental regulation of therapeutic response in cancer.

Florian Klemm1, Johanna A Joyce2.   

Abstract

The tumor microenvironment (TME) not only plays a pivotal role during cancer progression and metastasis but also has profound effects on therapeutic efficacy. In the case of microenvironment-mediated resistance this can involve an intrinsic response, including the co-option of pre-existing structural elements and signaling networks, or an acquired response of the tumor stroma following the therapeutic insult. Alternatively, in other contexts, the TME has a multifaceted ability to enhance therapeutic efficacy. This review examines recent advances in our understanding of the contribution of the TME during cancer therapy and discusses key concepts that may be amenable to therapeutic intervention.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  chemotherapy; immunotherapy; radiotherapy; stroma; therapeutic resistance; tumor microenvironment

Mesh:

Year:  2014        PMID: 25540894      PMCID: PMC5424264          DOI: 10.1016/j.tcb.2014.11.006

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  257 in total

1.  Aberrant type I and type III collagen gene expression in human breast cancer in vivo.

Authors:  S Kauppila; F Stenbäck; J Risteli; A Jukkola; L Risteli
Journal:  J Pathol       Date:  1998-11       Impact factor: 7.996

2.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

3.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

4.  A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.

Authors:  J-F Rossi; S Négrier; N D James; I Kocak; R Hawkins; H Davis; U Prabhakar; X Qin; P Mulders; B Berns
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

Review 5.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 6.  Breast cancer: should gastrointestinal bacteria be on our radar screen?

Authors:  Varada P Rao; Theofilos Poutahidis; James G Fox; Susan E Erdman
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

8.  Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts.

Authors:  Catherine C Park; Hui J Zhang; Evelyn S Yao; Chong J Park; Mina J Bissell
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth.

Authors:  Valentina Carito; Gloria Bonuccelli; Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Maria Cristina Caroleo; Erika Cione; Anthony Howell; Richard G Pestell; Michael P Lisanti; Federica Sotgia
Journal:  Cell Cycle       Date:  2012-08-23       Impact factor: 4.534

View more
  238 in total

1.  Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents.

Authors:  Leore T Geller; Ravid Straussman
Journal:  Mol Cell Oncol       Date:  2017-12-11

Review 2.  Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors:  Yu Yu; Jiuwei Cui
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

3.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

Review 4.  Genomic evolution of cancer models: perils and opportunities.

Authors:  Uri Ben-David; Rameen Beroukhim; Todd R Golub
Journal:  Nat Rev Cancer       Date:  2019-02       Impact factor: 60.716

5.  Remodeling the fibrotic tumor microenvironment of desmoplastic melanoma to facilitate vaccine immunotherapy.

Authors:  Hongda Zhu; Qi Liu; Lei Miao; Sara Musetti; Meirong Huo; Leaf Huang
Journal:  Nanoscale       Date:  2020-01-28       Impact factor: 7.790

Review 6.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

7.  Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma.

Authors:  Richard Fristedt; David Borg; Charlotta Hedner; Jonna Berntsson; Björn Nodin; Jakob Eberhard; Patrick Micke; Karin Jirström
Journal:  J Gastrointest Oncol       Date:  2016-12

Review 8.  Immunotherapy and tumor microenvironment.

Authors:  Haidong Tang; Jian Qiao; Yang-Xin Fu
Journal:  Cancer Lett       Date:  2015-10-19       Impact factor: 8.679

Review 9.  Acquired Resistance to Drugs Targeting Tyrosine Kinases.

Authors:  Steven A Rosenzweig
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

Review 10.  Circulating tumor cell interactions with macrophages: implications for biology and treatment.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Transl Lung Cancer Res       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.